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Table　1　Association of the CCL5-28C > G polymorphism with FEV1/FVC in nonasthmatic healthy adults
All participants (N = 1329) †Atopic participants (n = 783) Nonatopic participants (n = 546)
Genotype N ‡FEV1/FVC (%) N FEV1/FVC (%) N FEV1/FVC (%)
§CCL5-28CC 982 82.9 ± 0.18 567 83.1 ± 0.23 415 82.7 ± 0.27
-28CG 295 82.4 ± 0.32 192 82.8 ± 0.40 103 81.8 ± 0.53
-28GG  52 84.5 ± 0.76  24 83.8 ± 1.14  28 84.9 ± 1.02
†Atopy was defi ned as at least 1 positive response to 14 inhaled allergens.5
‡FEV1/FVC data are presented as the mean ± SE.
§General linear models were used to assess the associations between the CCL5-28C > G polymorphism and FEV1/FVC after adjusting 
for sex, age, and smoking status; p = 0.040, 0.70, and 0.026 for comparisons among all participants, atopic participants, and nonatopic par-
ticipants, respectively.
Dear Editor
The Opposite Effect of the CCL5 Gene on
Asthma and Baseline FEV1 in
Nonasthmatic Healthy Adults
A prominent aspect of the epithelial immune re-
sponse to common respiratory viruses, including RSV
infection, is the production and release of chemoki-
nes such as IL-8 and CCL5. By its recruitment of
memory T cells, monocytes, eosinophils, and baso-
phils, CCL5 is also implicated in chronic inflamma-
tory diseases such as asthma and chronic obstructive
pulmonary disease (COPD).
A recent genetic study of 59 infants with severe
RSV bronchiolitis and 201 controls reported that the
-28CG and GG genotypes at the regulatory region
of the CCL5 gene were protective against severe RSV
bronchiolitis.1 Surprisingly, this protective -28G allele
was associated with increased levels of mRNA ex-
pression and protein in vitro, and also with late onset
asthma and nonemphysematous COPD in our previ-
ous genetic studies.2,3
Given that accumulation of inflammatory immune
cells and airway wall remodeling processes are com-
mon characteristics in the small airways of patients
with asthma and COPD, we reasoned that the -28G
gain-of-function allele may be a common susceptibil-
ity factor to these inflammatory lung diseases, with la-
tent viral infections predisposing some patients to in-
creased epithelial remodeling and chronic hyperreac-
tivity.
Respiratory infections in childhood are also a sig-
nificant risk factor for airflow obstruction in adults.4
Therefore, we here examined the genetic impact of
this gain-of-function allele on levels of FEV1 using a
well-characterized nonasthmatic non-COPD healthy
population (N = 1329).5 Very interestingly, we found
that the homozygosity for the -28G allele was signifi-
cantly associated with higher levels of FEV1FVC.
The genetic effect of the -28G allele was stronger in
the nonatopic healthy participants (Table 1). These
results suggest that the gain-of-function promoter
polymorphism in CCL5 that causes susceptibility to
late-onset asthma and nonemphysematous COPD
might protect against reduction of FEV1 as well as se-
vere RSV bronchiolitis.
We also examined the genetic effects of the -28G
allele on the annual decline of FEV1 using partici-
pants who took the annual pulmonary function meas-
urements for at least 4 years of retrospective follow-
up (n = 821).5 The level of FEV1 at a given time point
in an individual depends on 2 potentially independent
processes: the maximum lung function obtained dur-
ing development and the rate of decline in lung func-
tion with age. We failed to see genetic effects of CCL5
on the annual decline of FEV1 (annual declines in
FEV1 were 22.8 [SE 1.1] mLyear, 26.4 [2.0] mL
year, and 18.8 [4.2] mLyear for the CC (n = 609), CG
(n = 174), and GG (n = 38)genotypes, respectively;
p = 0.15). Thus, abnormalities in lung development
during childhood, rather than accelerated decline in
lung function, could underlie the association between
FEV1FVC in healthy adults and the CCL5 genotype.
Interestingly, opposite effects of the genetic poly-
morphisms within IL8 on the development of asthma
and severe RSV infections have also been reported.6
These findings may partly reflect the diverse func-
tions of these chemokines. CCL5 has detrimental ef-
fects via the recruitment of immune cells that en-
hance pathological processes including airway inflam-
mation in asthma and COPD. In contrast, through its
location and production, CCL5 also has beneficial ac-
tivity by bringing immune cells to areas of infection
and injury. Host defense against viruses probably de-
pends on the targeted death of infected host cells and
then clearance of the cellular corpses by macro-
phages. For this process to be effective, the macro-
phage must avoid its own virus-induced death. CCL5-
CCR5 interaction provides antiapoptotic signals for
macrophage survival during viral infection.7 Such a
distinct role of CCL5 may partly explain why individu-
als with the gain-of-function allele at CCL5 are less
susceptible to severe viral bronchiolitis. As severe
bronchiolitis in infancy has been associated with a
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lower FEV1FVC ratio in adults,4 the -28G allele was
associated with better lung function in healthy adults
possibly through protection against severe viral infec-
tions during childhood. Therefore, we speculated that
the -28G gain-of-function allele acts to protect reduc-
tion of lung function, whereas it simultaneously acts
as a genetic risk factor for asthma and COPD. Our
finding may be in line with a recent large-scale,
consortium-based genomewide association study of
asthma that failed to support the contention that ge-
netic determinants of lung function influence suscep-
tibility to asthma.8
In conclusion, a series of genetic studies regarding
the CCL5 -28G allele in asthma, COPD, severe viral
bronchiolitis, and FEV1FVC may suggest that CCL5
has a distinct and perhaps even opposite role in these
conditions.
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